טוען...
Activity of Retapamulin (SB-275833), a Novel Pleuromutilin, against Selected Resistant Gram-Positive Cocci
Retapamulin (SB-275833), the first pleuromutilin to be developed for human topical use, was tested against a selected population of staphylococci and β-hemolytic streptococci. The MIC(90) results for retapamulin were 0.12 μg/ml for Staphylococcus aureus and ≤0.03 μg/ml for Streptococcus pyogenes; no...
שמור ב:
| Main Authors: | , , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
American Society for Microbiology
2006
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC1489758/ https://ncbi.nlm.nih.gov/pubmed/16801451 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.01432-05 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|